Zynlonta receives FDA accelerated approval for large B-cell lymphoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Zynlonta (loncastuximab tesirine-lpyl), a CD19-directed antibody and alkylating agent conjugate, was granted FDA Accelerated Approval for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

“Backwater to Blockbuster,” the first de novo book published by the Cancer History Project, traces the evolution of St. Jude Children’s Research Hospital to its current status of a powerhouse of research in pediatric cancer.

The U.S. Department of Justice issued a letter alleging that Yale Medical School of violating anti-discrimination laws and instititing policies that disadvantaged white and Asian applicants while favoring Black and Hispanic applicants.  The DOJ investigation, which was launched a year ago, reviewed the school’s admission policies for the class of 2023, 2024, and 2025, the...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login